MARKET

EVMN

EVMN

EVOMMUNE INC
NYSE
14.65
+0.58
+4.12%
After Hours: 14.71 +0.06 +0.39% 19:34 08/14 EDT
OPEN
13.94
PREV CLOSE
14.07
HIGH
14.68
LOW
13.94
VOLUME
362.59K
TURNOVER
--
52 WEEK HIGH
33.20
52 WEEK LOW
10.47
MARKET CAP
531.68M
P/E (TTM)
-9.5371
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)
TipRanks · 2d ago
Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)
TipRanks · 5d ago
Analysts Conflicted on These NA Names: TripAdvisor (TRIP), Evommune, Inc. (EVMN) and StandardAero, Inc. (SARO)
TipRanks · 5d ago
Weekly Report: what happened at EVMN last week (0803-0807)?
Weekly Report · 5d ago
Evommune Price Target Cut to $29.00/Share From $30.00 by RBC Capital
Dow Jones · 08/07 19:32
Evommune Is Maintained at Outperform by RBC Capital
Dow Jones · 08/07 19:32
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29
Benzinga · 08/07 19:21
Evommune, Inc. GAAP EPS of -$0.89
Seeking Alpha · 08/07 13:59
More
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Webull offers Evommune, Inc. stock information, including NYSE: EVMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVMN stock methods without spending real money on the virtual paper trading platform.